Skip to main
ALEC

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 25%
Strong Sell 0%

Bulls say

Alector Inc's innovative therapeutic approach focuses on neurodegeneration through its advancement of therapies that enhance immune function in the brain, supported by a promising pipeline that includes AL001, AL002, AL003, and AL101. The company's differentiated transferrin receptor binding and tunable ABC platform have demonstrated significant brain uptake in non-human primates while maintaining favorable safety signals, which positions Alector competitively in the CNS drug delivery landscape. Additionally, with key programs targeting large indications and the potential for multiple paths to shareholder value, early clinical proof-of-concept data could act as substantial catalysts for the stock's positive outlook.

Bears say

Alector Inc faces significant challenges following the failure of the INFRONT-3 trial of latozinemab, which did not meet its primary endpoint and raises translational biology concerns. The company is at risk of failing its ongoing clinical trials for key products AL001 and AL002, potentially impacting its regulatory approvals and peak revenue forecasts. Additionally, inefficiencies in PGRN transport may undermine the therapeutic potential of Alector's products, further exacerbating uncertainties around future performance and investment viability.

Alector Inc (ALEC) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 4 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.